Recruiting PHASE2 INTERVENTIONAL 3-arm NCT05227664

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Sponsor: Akeso

Conditions Locally Advanced Triple-negative Breast Cancer Metastatic Triple-negative Breast Cancer

Interventions AK112 AK117 Nab paclitaxel paclitaxel

Updated 7 times since 2022 Last updated: Mar 10, 2025 Started: Mar 23, 2022 Primary completion: Jul 30, 2025 Completion: Dec 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05227664, this PHASE2 trial focuses on Locally Advanced Triple-negative Breast Cancer and Metastatic Triple-negative Breast Cancer and remains actively recruiting participants. Sponsored by Akeso, it has been updated 7 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Apr 2025 — Present [monthly]

Recruiting PHASE2

Status: Unknown → Recruiting
Oct 2024 — Apr 2025 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2022 — Apr 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China
• Xiangyang, China